Suggested remit: To appraise the clinical and cost effectiveness of filgotinib within its marketing authorisation for treating axial spondyloarthritis.
- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Process:
- Cost Comparison Standard
- ID number:
- 6594
Project Team
- Project lead
- Jeremy Powell
Email enquiries
If you have any queries please email TACommB@nice.org.uk
- External Assessment Group:
- Kleijnen Systematic Reviews Ltd
Stakeholders
- Companies sponsors
- Alfasigma UK Ltd
- Others
- Department of Health and Social Care
- NHS England
- Patient carer groups
- None participating
- Professional groups
- Royal College of Physicians
- Associated public health groups
- Public Health Wales
- Comparator companies
- ADVANZ Pharma (golimumab) - confidentiality agreement not signed, not participating
- AbbVie (adalimumab, upadacitinib)
- Amgen (adalimumab) - confidentiality agreement not signed, not participating
- Biogen Biosimilars (adalimumab, etanercept, infliximab) - confidentiality agreement not signed, not participating
- Celltrion Healthcare (adalimumab, infliximab) - confidentiality agreement not signed, not participating
- Eli Lilly (ixekizumab) - confidentiality agreement not signed, not participating
- Fresenius Kabi (adalimumab) - confidentiality agreement not signed, not participating
- Janssen-Cilag (infliximab, golimumab) - confidentiality agreement not signed, not participating
- Novartis (secukinumab)
- Pfizer (etanercept, infliximab, tofacitinib) - confidentiality agreement not signed, not participating
- Sandoz (adalimumab, etanercept, infliximab) - confidentiality agreement not signed, not participating
- UCB Pharma (bimekizumab, certolizumab pegol) - confidentiality agreement not signed, not participating
- General commentators
- All Wales Therapeutics and Toxicology Centre
- Allied Health Professionals Federation
- British National Formulary (BNF)
- Department of Health - Northern Ireland
- Healthcare Improvement Scotland
- MHRA
- NHS Wales Joint Commissioning Committee
- Scottish Medicines Consortium
- Welsh Government
- Relevant research groups
- None participating
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 17 March 2026 | Invitation to participate |
| 15 December 2025 - 21 January 2026 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6594 |
| 15 December 2025 | In progress. Scoping commencing |
| 02 October 2025 | Note - Note added to the project documents |
| 15 May 2025 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
For further information on our processes and methods, please see our CHTE processes and methods manual